Studying modulation of calcium in cardiotoxicity induced by doxorubicin using vitamin D and vitamin B3
Heba Hossam El-Din Ahmed Awad;
Abstract
The aim of this study was to elucidate and compare the potential protective role of NAM and 1α(OH)D3 against DOX induced cardiotoxicity and to explore the possible molecular mechanism. The present study was divided into two parts. First: Screening the cardioprotective effect of NAM as well as 1α(OH)D3 against acute DOX cardiotoxicity. Second: Studying the cardioprotective effect of NAM and 1α(OH)D3 against chronic DOX cardiotoxicity
For screening the cardioprotective effect of NAM against acute DOX cardiotoxicity, 30 adult male rats were assigned to five groups as follow: control group, DOX group: rats were given a single i.p. injection of DOX (15 mg/kg) on the 7th day. The third, fourth & fifth groups (NAM groups): rats were given oral pretreatment of NAM at dose of 200, 400 and 600 mg/kg respectively for 7 days and the single i.p. DOX injection (15 mg/kg) on the 7th day after 1 h of the last treatment of NAM. For screening the cardioprotective effect of 1α(OH)D3 against acute DOX cardiotoxicity, 30 adult male rats were assigned to five groups as follow: control group, DOX group: rats were given a single i.p. injection of DOX (15 mg/kg) on the 7th day. Third group: were given i.p. injection of 1α(OH)D3at a dose of 0.5ug/Kg as pretreatment for 7 consecutive days and the single i.p. DOX injection on the 7th day after 1 h of the last treatment of 1α(OH)D3. The fourth group: were given single i.p. injection of 1α(OH)D3 at a dose of 0.5ug/Kg on the 5th day of the study only and i.p. DOX injection on the 7th day. The fifth group: were given single i.p. injection of 1α(OH)D3at a dose of 0.5ug/Kg one hour before i.p. DOX injection on the 7th day.
Based on serum cardiotoxicity markers as well as the histopathological examination, the optimal cardioprotective dose of NAM was 600 mg/kg and 1α(OH)D3 was 0.5 ug/kg 48 hours before DOX administration.
For studying the cardioprotective effect of NAM (600 mg/kg) and 1α(OH)D3 (0.5 ug/kg) against chronic DOX cardiotoxicity, sixty adult male Sprague Dawley rats were assigned randomly into six groups as follows; Control group were given distilled water through an oral gavage daily for 28 days., DOX group were given a single intraperitoneal (i.p.) injection of DOX (5 mg/kg) once a week for four consecutive weeks. The NAM+DOX group were given an oral dose of NAM (600 mg/kg) daily for 28 days and DOX (once weekly, 5mg/kg). The 1α(OH)D3+DOX group were given an i.p. injection of 1α(OH)D3 (0.5 ug/kg) once weekly, 48 hours before the DOX injection (once weekly, 5mg/kg) for four consecutive weeks. The NAM group were given NAM at an oral dose of 600 mg/kg daily for four consecutive weeks. The 1α(OH)D3group were given 1α(OH)D3 (0.5 ug/kg) i.p. once weekly for four consecutive weeks.
For screening the cardioprotective effect of NAM against acute DOX cardiotoxicity, 30 adult male rats were assigned to five groups as follow: control group, DOX group: rats were given a single i.p. injection of DOX (15 mg/kg) on the 7th day. The third, fourth & fifth groups (NAM groups): rats were given oral pretreatment of NAM at dose of 200, 400 and 600 mg/kg respectively for 7 days and the single i.p. DOX injection (15 mg/kg) on the 7th day after 1 h of the last treatment of NAM. For screening the cardioprotective effect of 1α(OH)D3 against acute DOX cardiotoxicity, 30 adult male rats were assigned to five groups as follow: control group, DOX group: rats were given a single i.p. injection of DOX (15 mg/kg) on the 7th day. Third group: were given i.p. injection of 1α(OH)D3at a dose of 0.5ug/Kg as pretreatment for 7 consecutive days and the single i.p. DOX injection on the 7th day after 1 h of the last treatment of 1α(OH)D3. The fourth group: were given single i.p. injection of 1α(OH)D3 at a dose of 0.5ug/Kg on the 5th day of the study only and i.p. DOX injection on the 7th day. The fifth group: were given single i.p. injection of 1α(OH)D3at a dose of 0.5ug/Kg one hour before i.p. DOX injection on the 7th day.
Based on serum cardiotoxicity markers as well as the histopathological examination, the optimal cardioprotective dose of NAM was 600 mg/kg and 1α(OH)D3 was 0.5 ug/kg 48 hours before DOX administration.
For studying the cardioprotective effect of NAM (600 mg/kg) and 1α(OH)D3 (0.5 ug/kg) against chronic DOX cardiotoxicity, sixty adult male Sprague Dawley rats were assigned randomly into six groups as follows; Control group were given distilled water through an oral gavage daily for 28 days., DOX group were given a single intraperitoneal (i.p.) injection of DOX (5 mg/kg) once a week for four consecutive weeks. The NAM+DOX group were given an oral dose of NAM (600 mg/kg) daily for 28 days and DOX (once weekly, 5mg/kg). The 1α(OH)D3+DOX group were given an i.p. injection of 1α(OH)D3 (0.5 ug/kg) once weekly, 48 hours before the DOX injection (once weekly, 5mg/kg) for four consecutive weeks. The NAM group were given NAM at an oral dose of 600 mg/kg daily for four consecutive weeks. The 1α(OH)D3group were given 1α(OH)D3 (0.5 ug/kg) i.p. once weekly for four consecutive weeks.
Other data
| Title | Studying modulation of calcium in cardiotoxicity induced by doxorubicin using vitamin D and vitamin B3 | Other Titles | دراسة التغيير فى الكالسيوم فى سمية القلب المحدثة بدواء الدوكسوربوسين باستخدام فيتامين د و ب 3 | Authors | Heba Hossam El-Din Ahmed Awad | Issue Date | 2021 |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| BB9187.pdf | 6.22 MB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.